[go: up one dir, main page]

NO982562D0 - Composition for the treatment of pain - Google Patents

Composition for the treatment of pain

Info

Publication number
NO982562D0
NO982562D0 NO982562A NO982562A NO982562D0 NO 982562 D0 NO982562 D0 NO 982562D0 NO 982562 A NO982562 A NO 982562A NO 982562 A NO982562 A NO 982562A NO 982562 D0 NO982562 D0 NO 982562D0
Authority
NO
Norway
Prior art keywords
pain
treatment
composition
Prior art date
Application number
NO982562A
Other languages
Norwegian (no)
Other versions
NO982562L (en
Inventor
Charles H Mitch
Harlan E Shannon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO982562D0 publication Critical patent/NO982562D0/en
Publication of NO982562L publication Critical patent/NO982562L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO982562A 1995-12-07 1998-06-04 Composition for the treatment of pain NO982562L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US829995P 1995-12-07 1995-12-07
PCT/US1996/019309 WO1997020561A1 (en) 1995-12-07 1996-12-05 Composition for treating pain

Publications (2)

Publication Number Publication Date
NO982562D0 true NO982562D0 (en) 1998-06-04
NO982562L NO982562L (en) 1998-07-10

Family

ID=21730869

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982562A NO982562L (en) 1995-12-07 1998-06-04 Composition for the treatment of pain

Country Status (13)

Country Link
EP (1) EP0871445A4 (en)
JP (1) JP2000501709A (en)
KR (1) KR19990071976A (en)
CN (1) CN1208349A (en)
AU (1) AU705031B2 (en)
CA (1) CA2238815A1 (en)
CZ (1) CZ174698A3 (en)
EA (1) EA199800533A1 (en)
IL (1) IL124419A0 (en)
NO (1) NO982562L (en)
NZ (1) NZ324988A (en)
PL (1) PL327137A1 (en)
WO (1) WO1997020561A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046227A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
WO2000075140A1 (en) 1999-06-04 2000-12-14 Eli Lilly And Company 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US12396988B2 (en) * 2019-04-04 2025-08-26 Board Of Regents, The University Of Texas System Methods of using muscarinic antagonists in the treatment of depression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998450A (en) * 1958-05-19 1961-08-29 Warner Lambert Pharmaceutical Process of preparing nu-acetyl-p-amino phenol
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5260293A (en) * 1988-01-30 1993-11-09 Merck Sharp & Dohme Limited Pyrazines, pyrimidines and pyridazines useful in the treatment of senile dementia
IL89351A0 (en) * 1988-03-14 1989-09-10 Lundbeck & Co As H 4,5,6,7-tetrahydroisothiazolo(4,5-c)pyridines,process for their preparation and pharmaceutical compositions containing them
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2185805A1 (en) * 1994-03-18 1995-09-28 Georg Frank Low dosage ketoprofen

Also Published As

Publication number Publication date
WO1997020561A1 (en) 1997-06-12
AU705031B2 (en) 1999-05-13
CZ174698A3 (en) 1998-10-14
JP2000501709A (en) 2000-02-15
CN1208349A (en) 1999-02-17
PL327137A1 (en) 1998-11-23
EP0871445A1 (en) 1998-10-21
CA2238815A1 (en) 1997-06-12
NZ324988A (en) 1999-08-30
AU1279197A (en) 1997-06-27
IL124419A0 (en) 1998-12-06
NO982562L (en) 1998-07-10
EA199800533A1 (en) 1999-02-25
KR19990071976A (en) 1999-09-27
EP0871445A4 (en) 2001-01-10

Similar Documents

Publication Publication Date Title
NO982172D0 (en) Use of epinastine for the treatment of pain
NO976063D0 (en) Procedure for the treatment of diabetes
FI973292A7 (en) Substituted isoxazoles for the treatment of inflammation
NO984431D0 (en) Procedure for treating pain
FI962249A7 (en) Substituted pyrazolylbenzenesulfonamides for the treatment of inflammation
ATE235481T1 (en) SUBSTITUTED BENZOPYRANE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION
NO965377L (en) Indolinone compounds for the treatment of diseases
NO991381D0 (en) Combination therapy for the treatment of psychoses
NO934547D0 (en) Oral treatment of Helicobacter-in-infection
NO963785D0 (en) Process for the treatment of 5HT2B receptor-related conditions
NO990225D0 (en) Medications for the treatment of hyperphosphatemia
DE69626993D1 (en) WOUND TREATMENT COMPOSITION
NO991459L (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
DE69620691D1 (en) Therapeutic agent for the treatment of hypercholesterolemia
IL118289A0 (en) The use of glyceryl triacetate for treatment of onychomycoses
DE69622461D1 (en) Surface treatment composition
NO984432D0 (en) Procedure for the treatment of migraine pain
NO984446D0 (en) Procedure for treating pain
NO982562D0 (en) Composition for the treatment of pain
NO982582D0 (en) Procedure for treating pain
EE9700235A (en) Benzenamides for the treatment of neurodegenerative diseases
NO973366D0 (en) Procedure for the treatment of multiple sclerosis
BR9610382A (en) Cableo treatment composition
GB9510162D0 (en) Compositions for the treatment of skin conditions
NO991158L (en) Procedure for the treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application